Navigation Links
Stem Cell Study Shows Benefits in Treatment of Spinal Injuries

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries -- SEOUL, South Korea, November 10, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries


Results of 108 Patients Demonstrate Safety and Efficacy

SEOUL, South Korea, November 10, 2010 /PRNewswire/ -- Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI). Speaking at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010, Dr. Shroff explained her treatment protocol and clinical results, demonstrating the safety and efficacy of her human embryonic stem cell (hESC) therapy. The groundbreaking study was conducted on 108 chronic SCI patients treated by Dr. Shroff over a 6 year period-2004 to 2009. Dr Geeta Shroff also shared her vision, which is to see hESC therapy available globally as the first line of treatment for many of mankind's worst afflictions and her willingness to collaborate with entities and work with regulatory authorities worldwide, to realise this vision.

About the hESC Technology

Dr. Geeta Shroff has developed a commercially viable technology to isolate hESC, culture them, prepare them for clinical application and store them in ready-to-use form with a shelf life of six months. This technology, which has patents applied for worldwide, provides a safe and effective, 'purely human' product, for the treatment of a wide range of medical conditions. The ready-to-use product is universally acceptable as it does not require any cross- matching and has a shelf life of 6 months, making it amenable to global marketing. The technology is being used clinically to treat many conditions including spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Since 2002, more than 800 patients from 35 countries have been treated at Nutech Mediworld, New Delhi and the number is steadily growing.

For further information, please contact: Nutech Mediworld

SOURCE Nutech Mediworld
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Study Shows Cardiovascular Deaths in Europe Could Be Prevented
2. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Arizona State University awarded $6.5 million to study nanotechnology and society
5. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
6. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. CoreLab Partners Completes First TQT Study in Japan
9. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
10. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
11. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):